HC Wainwright Has Bearish Estimate for AVTX FY2025 Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Investment analysts at HC Wainwright lowered their FY2025 earnings per share estimates for shares of Avalo Therapeutics in a note issued to investors on Monday, November 24th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($7.22) per share for the year, down from their previous forecast of ($6.82). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2025 earnings at ($1.74) EPS, Q1 2026 earnings at ($1.76) EPS, Q2 2026 earnings at ($1.61) EPS, Q3 2026 earnings at ($1.63) EPS, Q4 2026 earnings at ($1.65) EPS and FY2026 earnings at ($6.64) EPS.

AVTX has been the subject of several other reports. Cowen initiated coverage on Avalo Therapeutics in a report on Friday, September 5th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Tuesday, October 14th. Cantor Fitzgerald assumed coverage on shares of Avalo Therapeutics in a report on Friday, August 15th. They set an “overweight” rating on the stock. TD Cowen assumed coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a research report on Monday, September 29th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $31.67.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $18.55 on Wednesday. The company has a 50 day moving average price of $15.25 and a 200-day moving average price of $9.62. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $19.41. The company has a market capitalization of $336.31 million, a PE ratio of -3.46 and a beta of 0.94.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52).

Institutional Trading of Avalo Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. BIT Capital GmbH purchased a new position in Avalo Therapeutics in the 3rd quarter worth $25,000. ADAR1 Capital Management LLC acquired a new position in shares of Avalo Therapeutics in the first quarter valued at about $80,000. Quadrature Capital Ltd purchased a new position in shares of Avalo Therapeutics in the second quarter worth about $55,000. Dimensional Fund Advisors LP purchased a new position in shares of Avalo Therapeutics in the third quarter worth about $143,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics during the second quarter worth about $56,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.